ABSTRACT
We report the results of a chemotherapy regimen combining oxaliplatin, 5-fluorouracil, and folinic acid in patients with metastatic renal cell carcinoma. The objective of this pilot study was to define the potential efficacy of this second-line combination in patients previously treated with interleukin-2 alone or in combination with interferon alpha. Fourteen patients with metastatic renal cell carcinoma in failure after immunotherapy were included in this trial. During treatment, patients received six chemotherapy courses (Folfox regimen) administered every 2 weeks. Each cycle combined oxaliplatin day (D) D1 and folinic acid plus 5-fluorouracil D1 and D2. At completion of treatment, no objective response was observed and two patients presented stable disease. This chemotherapy schedule in patients with metastatic renal cell carcinoma previously treated with immunotherapy does not seem to be effective.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma/drug therapy , Kidney Neoplasms/drug therapy , Aged , Carcinoma/secondary , Female , Fluorouracil/administration & dosage , Humans , Immunotherapy , Interferon-alpha/therapeutic use , Interleukin-2/therapeutic use , Kidney Neoplasms/secondary , Leucovorin/administration & dosage , Male , Middle Aged , Organoplatinum Compounds , Pilot Projects , PrognosisABSTRACT
Owing to its technical difficulty and to an imperfect knowledge of its semiology, lymphography of the upper limb is rarely used. However, experience makes it easy to perform and of considerable value and reliability for diagnostic purposes. Its main advantage in patients with palpable lymphadenopathy is that lymph node excision can be avoided in many cases provided the subjects are regularly followed up.
